A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
This aim of study is to evaluate the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy by a randomized, double-blind, placebo-controlled trial.
Cancer
DRUG: Olanzapine
complete response rate for the acute phase (0-24 hours) after chemotherapy, during 24 hours after first cycle of moderately emetogenic chemotherapy (MEC)
complete response rate for the delayed phase (24-120 hours) and overall phase (0-120 hours) after chemotherapy, during 0-120 hours after first cycle of MEC|no vomiting for the overall phase, during 0-120 hours after first cycle of MEC|significant emesis for the overall phase, during 0-120 hours after first cycle of MEC|numbers and time for rescue medicaions, during 0-120 hours after first cycle of MEC|effects on quality of life by FLIE questionnaire, during 0-120 hours after first cycle of MEC
This aim of study is to evaluate the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy by a randomized, double-blind, placebo-controlled trial.